- WebCafé home
- Newly Diagnosed
- Treatment Options
- Non-Invasive blc
- Invasive bladder cancer
- Upper tract TCC
- Metastatic cancer
- Clinical trials
- Survival Guides
- Resources USA & Canada
- Resources Europe
- Clinical trials
- Alternative medicine
- Financial help
- About Us
For a list of European hospitals using Hexvix see below.
Gold Standard Becomes Platinum:
Photodynamic Diagnosis (PDD), fluorescent, blue light cystoscopy -
Hexvix identifies approximately 30% more patients with CIS (carcinoma in situ) compared to standard cystoscopy.
Although the use of fluorescence cystoscopy/PDD improves the detection rate of CIS to more than 95 % it has not yet been implemented on a regular basis in daily practice. The European Association of Urology's latest guidelines represent state-of-the-art recommendations, and use of fluorescent cystoscopy is now included in their guidelines for non-invasive bladder cancer.
A solution is instilled into the bladder and held for one hour before the florescent light cystoscopy is performed. There are no side effects apart from those expected after a regular white light cystoscopy is performed. 2.4% of adverse side effects were thought to be product related in the largest clinical trial to date. 3
Jan. '05:GE Healthcare, a unit of General Electric Company (NYSE:GE), and PhotoCure ASA (OSE:PHO) announced a licensing agreement that grants GE Healthcare an exclusive option for GE Healthcare to market and distribute the product in the US.
Update, Journal of Urology, 7-'07:
Barnet and Chase Farm
Guys and St Thomas
UCLH (University College London Hospital)
Castle Hill (Hull)
BMI Hampshire Clinic
Chelsea and Westminster
Leicester Royal Infirmary
Adelaide and Meath (Dublin)
NL Hospitals Using Hexvix
This is not yet a complete list.
1. Pub Med Abstract: Bladder carcinoma in situ in 2003: state of the art. Witjes JA. Department of Urology, University Medical Center St Radboud, Nijmegen, The Netherlands. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. Jocham D, Witjes F, Wagner S, Zeylemaker B, van Moorselaar J, Grimm MO, Muschter R, Popken G, Konig F, Knuchel R, Kurth KH. Department of Urology, University of Schleswig-Holstein, Lubeck, Germany. J Urol. 2005 Sep;174(3):862-6; discussion 866.
|Last Updated ( Tuesday, 16 September 2008 )|